Angeles Investment Advisors LLC Sells 978 Shares of Sanofi (NASDAQ:SNY)

Angeles Investment Advisors LLC lessened its position in Sanofi (NASDAQ:SNY) by 8.1% in the second quarter, HoldingsChannel.com reports. The fund owned 11,113 shares of the company’s stock after selling 978 shares during the period. Angeles Investment Advisors LLC’s holdings in Sanofi were worth $539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. TCTC Holdings LLC grew its stake in Sanofi by 28.0% during the first quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC boosted its position in shares of Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after acquiring an additional 221 shares in the last quarter. Wynn Capital LLC boosted its position in shares of Sanofi by 4.5% during the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after acquiring an additional 226 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Sanofi by 5.3% in the fourth quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company’s stock valued at $250,000 after acquiring an additional 255 shares during the last quarter. Finally, Bruce G. Allen Investments LLC raised its position in Sanofi by 4.3% during the first quarter. Bruce G. Allen Investments LLC now owns 6,347 shares of the company’s stock valued at $308,000 after purchasing an additional 261 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SNY shares. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th. Argus raised their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $57.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $57.13 on Monday. Sanofi has a one year low of $42.63 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $144.69 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 1.60 and a beta of 0.60. The firm has a 50 day simple moving average of $53.67 and a 200 day simple moving average of $50.17.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the prior year, the company earned $0.95 EPS. Sanofi’s revenue was up 7.8% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.25 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.